Thomas Steyer’s Heron Therapeutics HRTX Stock Holding History

Thomas Steyer’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-875,000	Closed	-$20.6M	–	109
2019 Q4	$20.6M	Buy	+875,000	New	+$19.4M	0.14%	86

Other funds holding HRTX

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Thomas Steyer's HRTX Position: Q1 2020 in Review

Thomas Steyer sold out of Heron Therapeutics (HRTX) in Q1 2020, closing a stake of 875,000 shares — an estimated $20.6M sold.

Thomas Steyer first reported a position in HRTX in Q4 2019 and held it in 1 quarter. The position peaked at $20.6M in Q4 2019. 193 funds tracked by Wall St. Rank hold HRTX as of Q1 2020.

Thomas Steyer reported no remaining Heron Therapeutics position as of Q1 2020 after selling out during the quarter.
Thomas Steyer sold 875,000 Heron Therapeutics shares in Q1 2020, an estimated $20.6M.
Thomas Steyer first reported a position in Heron Therapeutics in Q4 2019 and held it in 1 quarter.
Thomas Steyer's Heron Therapeutics position peaked at $20.6M in Q4 2019.
193 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2020.

Based on Farallon Capital Management's 13F filing for Q1 2020, filed 15 May 2020.